Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease

BACKGROUND: Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate. AIM: To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation t...

Descripción completa

Detalles Bibliográficos
Autores principales: Calafat, Margalida, González-Muñoza, Carlos, Fortuny, Marta, Roig, Cristina, Calm, Anna, Mombiela, Antonio, Cañete, Fiorella, Bertoletti, Federico, González-González, Laura, Teller-Martín, Marta, Gordillo, Jordi, Mañosa, Míriam, Garcia-Planella, Esther, Domènech, Eugeni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221095/
https://www.ncbi.nlm.nih.gov/pubmed/34164799
http://dx.doi.org/10.1007/s40520-021-01917-9
Descripción
Sumario:BACKGROUND: Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate. AIM: To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS. METHODS: IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded. RESULTS: Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died. CONCLUSIONS: Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS.

Ejemplares similares